Impact of immunomodulating therapy on morbidity in patients with severe sepsis

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 3, 1999, Pages 852-857

  Pittet, Didier ^a   Harbarth, Stephan ^b   Suter, Peter M ^b   Reinhart, Konrad ^b   Leighton, Anton ^b   Barker, Christopher ^b   Macdonald, Frances ^b   Abraham, Edward ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G; LENERCEPT; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; HUMAN; IMMUNOMODULATION; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS;

EID: 0032863001     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.3.9809033     Document Type: Article

References (35)

1. Fein, A. M., M. Lippmann, H. Holtzman, A. Eliraz, and S. K. Goldberg, 1983. The risk factors, incidence, and prognosis of ARDS following septicemia. Chest 83:40-42.
2. Parrillo, J. E., M. M. Parker, C. Natanson, A. F. Suffredini, R. L. Danner, R. E. Cunnion, and F. P. Ognibene. 1990. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann. Intern. Med. 113:227-242.
3. Rangel-Frausto, S. M., D. Pittet, M. Costigan, T. S. Hwang, C. S. Davis, and R. P. Wenzel. 1995. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. J.A.M.A. 273: 117-123.
4. Valles, J., C. Leon, and F. Alvarez-Lerma. 1997. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis: Spanish collaborative group for infections in intensive care units. Clin. Infect. Dis. 24:387-395.
5. Pittet, D., B. Thiévent, R. P. Wenzel, N. Li, R. Auckenthaler, and P. M. Suter. 1996. Bedside prediction of mortality from bacteremic sepsis: a dynamic analysis of ICU patients. Am. J. Respir. Crit. Care Med. 153: 684-693.
6. Pittet, D., D. Tarara, and R. P. Wenzel. 1994. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. J.A.M.A. 271:1598-1601.
7. van der Poll, T., H. R. Buller, H. ten Cate, C. H. Wortel, K. A. Bauer, S. J. van Deventer, C. E. Hack, H. P. Sauerwein, R. D. Rosenberg, and J. W. ten Cate. 1990. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N. Engl. J. Med. 322: 1622-1627.
8. Leeper-Woodford, S. K., P. D. Carey, K. Byrne, J. K. Jenkins, B. J. Fisher, C. Blocher, H. J. Sugerman, and A. A. Fowler, 3d. 1991. Tumor necrosis factor. Am. Rev. Respir. Div. 143(5, Pt. 1):1076-1082.
9. Damas, P., A. Reuter, P. Gysen, J. Demonty, M. Lamy, and P. Franchimont. 1989. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit. Care Med. 17:975-978.
10. Waage, A., A. Halstensen, and T. Espevik. 1987. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1:355-357.
11. Grau, G. E., T. E. Taylor, M. E. Molyneux, J. J. Wirima, P. Vassalli, M. Hommel, and P. H. Lambert. 1989. Tumor necrosis factor and disease severity in children with falciparum malaria. N. Engl. J. Med. 320:1586-1591.
12. Kwiatkowski, D., A. V. Hill, I. Sambou, P. Twumasi, J. Castracane, K. R. Manogue, A. Cerami, D. R. Brewster, and B. M. Greenwood. 1990. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 336:1201-1204.
13. Tracey, K. J., Y. Fong, and D. G. Hesse. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662-664.
14. Opal, S. M., A. S. Cross, N. M. Kelly, J. C. Sadoff, M. W. Bodmer, J. E. Palardy, and G. H. Victor. 1990. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. J. Infect. Dis. 161: 1148-1152.
15. Walsh, C. J., H. J. Sugerman, P. G. Mullen, P. D. Carey, S. K. Leeper-Woodford, G. J. Jesmok, E. F. Ellis, and A. A. Fowler. 1992. Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine Gram-negative sepsis. Arch. Surg. 127: 138-144; Discussion 144-145.
16. Abraham, E., R. Wunderink, H. Silverman, T. M. Perl, S. Nasraway, H. Levy, R. Bone, R. P. Wenzel, R. Balk, R. Allred, and the TNF-alpha MAb Sepsis Study Group. 1995. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. J.A.M.A. 273:934-941.
17. Reinhart, K., C. Wiegand-Lohnert, F. Grimminger, M. Kaul, S. Withington, D. Treacher, J. Eckart, S. Willatts, C. Bouza, D. Krausch, F. Stockenhuber, J. Eiselstein, L. Daum, and J. Kempeni. 1996. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock. Crit. Care Med. 24:733-742.
18. Cohen, J., and J. Carlet. 1996. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit. Care Med. 24:1431-1440.
19. Fisher, C. J., Jr., J. M. Agosti, S. M. Opal, S. F. Lowry, R. A. Balk, J. C. Sadoff, E. Abraham, R. M. Schein, and E. Benjamin. 1996. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N. Engl. J. Med. 334:1697-1702.
20. Abraham, E., M. P. Glauser, T. Butler, J. Garbino, D. Gelmont, P. F. Laterre, K. Kudsk, H. A. Bruining, C. Otto, E. Tobin, and the RO 45-2081 Study Group. 1997. P55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. J.A.M.A. 277:1531-1538.
21. Hinshaw, L. B., T. E. Emerson, Jr., F. B. Taylor, Jr., A. C. Chang, M. Duerr, G. T. Peer, D. J. Flournoy, G. L. White, S. D. Kosanke, and C. K. Murray. 1992. Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J. Trauma 33: 568-573.
22. Jin, H., R. Yang, S. A. Marsters, S. A. Bunting, F. M. Wurm, S. M. Chamow, and A. Ashkenazi. 1994. Protection against rat endotoxic shock by p55 tumor necrosis factor (TNF) receptor immunoadhesin: comparison with anti-TNF monoclonal antibody. J. Infect. Dis. 170:1323-1326.
23. Bernard, G. R., A. P. Wheeler, J. A. Russell, R. Schein, W. R. Summer, K. P. Steinberg, W. J. Fulkerson, P. E. Wright, B. W. Christman, W. D. Dupont, S. B. Higgins, B. B. Swindell, and the Ibuprofen in Sepsis Study Group. 1997. The effects of ibuprofen on the physiology and survival of patients with sepsis. N. Engl. J. Med. 336:912-918.
24. Schulman, K. A., H. A. Glick, H. Rubin, and J. M. Eisenberg. 1991. Cost-effectiveness of HA-1A monoclonal antibody for Gram-negative sepsis: economic assessment of a new therapeutic agent. J.A.M.A. 266: 3466-3471.
25. Chalfin, D. B., M. E. Holbein, A. M. Fein, and G. C. Carlon. 1993. Cost-effectiveness of monoclonal antibodies to Gram-negative endotoxin in the treatment of Gram-negative sepsis in ICU patients. J.A.M.A. 269:249-254.
26. Petros, A. J., J. C. Marshall, and H. K. F. Van Saene. 1995. Should morbidity replace mortality as an endpoint for clinical trials in intensive care? Lancet 345:369-371.
27. Hebert, P. C., A. J. Drummond, J. Singer, G. R. Bernard, and J. A. Russell. 1993. A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest 104:230-235.
28. Knaus, W. A., F. E. Harrell, C. J. Fisher, D. P. Wagner, S. M. Opal, J. C. Sadoff, E. A. Draper, C. A. Walawander, K. Conboy, and T. H. Grasela. 1993. The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. J.A.M.A. 270:1233-1241.
29. Kaplan, E. L., and P. Meier. 1958. Nonparametric estimation from incomplete information. J. Am. Stat. Assoc. 53:457-481.
30. Pepe, M. S. 1991. Inference for events with dependent risks in multiple endpoint studies. J. Am. Stat. Assoc. 86:770-778.
31. Efron, B., and R. Tibshirani, editors. 1993. An Introduction to the Bootstrap. Chapman and Hall, New York.
32. Barriere, S. L., and B. J. Guglielmo. 1992. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies. Clin. Pharm. 11:223-235.
33. Vincent, J. L., D. J. Bihari, P. M. Suter, H. A. Bruining, J. White, M.-H. Nicolas-Chanoin, M. Wolff, R. C. Spencer, and M. Hemmer. 1995. The prevalence of nosocomial infection in intensive care units in Europe: results of the European Prevalence of Infection in Intensive Care (EPIC) Study. J.A.M.A. 274:639-644.
34. Pittet, D., and S. Harbarth. 1998. The intensive care unit. In J. V. Bennett and P. S. Brachman, editors. Hospital Infections, 4th ed. Little, Brown, Boston. 381-402.
35. Yusuf, S., J. Wittes, J. Probstfield, and H. A. Tyroler. 1991. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. J.A.M.A. 266:93-98.